TapImmune to Present at Two Upcoming Investor Conferences

JACKSONVILLE, Fla., March 14, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the Sachs BioCapital USA Forum, held March 21^st, 2018. He will also give a company presentation and live webcast at the 26^th Annual Wall Street Investor Forum, held March 22^nd, 2018. Both conferences will take place in New York City.

Sachs BioCapital USA Forum
Future of IO: Technologies & Market Opportunities Panel
Date: Wednesday, March 21, 2018
Time: 10:15 AM (Eastern Time)
Location: New York Academy of Sciences, Plenary Room

TapImmune Company Presentation
Date: Wednesday, March 21, 2018
Time: 3:00 PM (Eastern Time)
Location: The New York Academy of Sciences, Plenary Room (Presenting Track B)

26^th Annual Wall Street Investor Forum
TapImmune Company Presentation
Date: Thursday, March 22, 2018
Time: 11:05 AM (Eastern Time)
Location: The University Club of NYC, 9^th Floor (Track 1)

The audio webcast of the 26th Annual Wall Street Investor Forum will be accessible via the News and Events section of the TapImmune website: https://tapimmune.com/events. An archive of the audio will remain available for 90 days following the presentation.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

For additional information, please visit: https://tapimmune.com/

To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

SOURCE TapImmune Inc.

Related Links

www.tapimmune.com